title: Treatment of lower torso stages I and II Hodgkin's disease with radiation with or without adjuvant mechlorethamine, vincristine, procarbazine, and prednisone.
abstract: From 1956 to 1987, 60 patients with either lymphangiogram-staged or laparotomy-staged I-II lower torso presentations of Hodgkin's disease were treated with radiation with or without Mustargen (mechlorethamine), vincristine, procarbazine, and prednisone (MOPP). In 22 with inguinal/femoral or pelvic disease and 24 with abdominal disease, treatment consisted of radiation only. Fourteen other patients with abdominal disease received MOPP chemotherapy before radiotherapy. In 11, the chemotherapy was limited to two cycles. At 10 years, the determinate survival and freedom from progression rates for all patients were 82% and 72%, respectively. For patients with inguinal/femoral or pelvic disease who were treated with radiation only, the corresponding rates were 90% and 86%. For patients with abdominal disease who received radiation only, the determinate survival and the freedom from progression rates were only 66% and 50%, respectively. However, corresponding results for 14 patients with abdominal disease who were treated with MOPP and radiation were 100% and 92% (P = 0.033 and P = 0.009, respectively.
authors.affiliation: Department of Clinical Radiotherapy, University of Texas M. D. Anderson Cancer Center, Houston 77030.
authors.forename: S S
authors.initials: SS
authors.lastname: Givens
authors.forename: L M
authors.initials: LM
authors.lastname: Fuller
authors.forename: F B
authors.initials: FB
authors.lastname: Hagemeister
authors.forename: E A
authors.initials: EA
authors.lastname: Gehan
mesh_terms: D000008:Abdominal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006689:Hodgkin Disease / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D007264:Inguinal Canal / Q000473:pathology; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage; D009367:Neoplasm Staging; D010386:Pelvic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy; D011241:Prednisone / Q000008:administration & dosage; D011344:Procarbazine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone